Medical Research
Beyond LDL: The New Lipid Targets Reshaping Cardiovascular Risk
Human genetics is guiding a fresh class of lipid drugs — Lp(a) inhibitors and lipoprotein-lipase activators — aimed at the residual heart risk statins can't reach.